Indefinite Delivery Contract HHSN261201500041I

The National Cancer Institute awarded a multiple-award Indefinite Delivery Contract to The Institute For Cancer Research on January 25, 2019, for preclinical drug development and biomarker services supporting the PREVENT Cancer Preclinical Drug Development Program, with a ceiling of $74,995,000 and an ultimate completion date of January 24, 2024. Work is performed at The Institute For Cancer Research's facility in Philadelphia, Pennsylvania. The Institute is a non-profit subsidiary of Temple...

The National Cancer Institute awarded a multiple-award indefinite delivery contract to The University of Texas M.D. Anderson Cancer Center on January 25, 2019, with a ceiling value of $74,995,000 and ultimate completion date of January 24, 2024, for the PREVENT Preclinical Drug Development Program focused on preclinical efficacy testing and intermediate biomarker evaluation of cancer preventive agents. Work is performed in Houston, Texas. The IDIQ supports systematic preclinical evaluation of...

The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a single award indefinite delivery contract to International Aids Vaccine Initiative Inc. to provide preclinical services supporting the development of biopharmaceutical therapeutics and diagnostics for infectious diseases. The potential value of the contract is $30 million with a performance period from January 2023 through September 2030. Services will be delivered under five task areas: product...

This indefinite delivery contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health within the Department of Health and Human Services, to IIT Research Institute (IITRI), a non-profit contract research organization. The $74,995,000 multiple-award contract, titled the "PREVENT Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarkers," supports preclinical efficacy and biomarker evaluation, manufacturing, and...

The National Institute of Allergy and Infectious Diseases awarded an indefinite-delivery contract to Colorado State University with a ceiling of $107,274,471 on October 15, 2020, to provide preclinical development support for candidate products and drug development activities ranging from initial product discovery through activities required to support clinical trials and product licensure. This is a multiple-award IDIQ with no set-aside applied to the prime contract, though the underlying...

This indefinite delivery contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to provide preclinical development support for candidate products addressing HIV, HBV, HCV and other infectious diseases. The multiple award ID/IQ contract holds a potential value of $107 million and a period of performance from October 2020 through October 2027. The contract establishes seven task areas for procuring services such as in vitro testing,...

This federal indefinite delivery contract was awarded by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, to the non-profit IIT Research Institute (IITRI). The $19 million PREVENT Toxicology and Pharmacology Testing (PREVENT TOX) IDIQ contract vehicle enables NCI to efficiently access IITRI's preclinical research capabilities on an as-needed basis to support the development of cancer prevention therapies. Task orders issued under this...

The National Institute of Allergy and Infectious Diseases awarded an indefinite-delivery contract to The Charles Stark Draper Laboratory, Inc., with a ceiling of $146.3 million and an award date of July 15, 2024. This is a single-award vehicle with no set-aside. The contract procures animal and replacement models of infectious diseases for preclinical evaluation. Place of performance is not specified in the source. The period of performance extends from the award date through July 14, 2031....

The National Institute of Allergy and Infectious Diseases awarded an indefinite-delivery, multiple-award contract to Sri International on October 15, 2020, with a ceiling of $107.3 million for preclinical development support for HIV therapeutics, concluding October 14, 2027. The IDIQ encompasses preclinical services ranging from initial product discovery through activities supporting clinical trials and product licensure across seven task areas: in vitro testing, synthesis of therapeutic agents,...

The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute (NCI) awarded a multiple-award indefinite delivery/indefinite quantity (IDIQ) contract to Weill Medical College of Cornell University to provide preclinical research services for the PREVENT Cancer Preclinical Drug Development Program. Under this $149,995,000 IDIQ, the contractor performs efficacy testing, biomarker evaluation, and analytical assay development to advance cancer...